Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Srikanth Singamaneni
Washington University, Department: Anesthesiology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Auragent Biosciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
It was determined Dr. Singmaneni’s personal financial relationship with Auragent Biociences, related to the above referenced research, creates a financial conflict of interest due to the following reasons:
• The primary focus of Auragent, an entity with which Dr. Singmaneni owns equity, is to commercialize the the IP, entitled “Plasmonic Skin as a Universal Fluoresence Enhancer” being developed and evaluated in the above mentioned research.
• Since Dr. Singmaneni owns equity in the company and will earn royalties from the sale and distribution of the IP, Dr. Singmaneni could directly benefit should the company’s equity value increase as a result of the study.
• Dr. Singmaneni’s role, as identified below, could directly affect the study.
While it was determined financial conflicts of interest exist, sufficient mechanisms exist to ensure the objectivity and integrity of the research, based on the following reasons:
• The research is basic in nature and in its early stages.
• Dr. Singamaneni has no access to patients or PHI, and is not on listed on the human study applications.
• The associated human studies are low risk studies that collect urine samples to be used in assays.
• Additionally, a plan has been developed to mitigate the financial conflict of interest, which is outlined below.
NANOTECH BIOMARKERS FOR RENAL CANCER INTERVENTION: CLINICAL VALIDATION & UTILITY
Renal cell carcinoma (RCC) is the most lethal urologic malignancy with an incidence exceeding that of leukemia and pancreatic cancer in men, and that of ovarian and pancreatic cancer in women. It now accounts for almost 4% of adult malignancies. Due to increased general diagnostic use of abdominal imaging, the incidental discovery of occult small renal masses has increased. However, radiologic screening is impractical, expensive, and cannot reliably differentiate RCC from a benign mass. The unmet need is a sensitive and specific tumor marker for the differential diagnosis of imaged renal masses and population screening to detect RCC We have identified novel urine biomarkers of RCC, determined their clinical validity, and developed nanotechnology-based assays for these markers. Here we determine the clinical utility of the nano-assays in a 25,000 patient screening protocol. Successful completion will provide a non-invasive means of detecting kidney cancer and an adjunct to accurately diagnose renal images.
Filed on July 25, 2018.
Tell us what you know about Srikanth Singamaneni's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Srikanth Singamaneni”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Srikanth Singamaneni | Washington University | Conflict of Interest | Auragent Biosciences | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.